Abstract
Animal models of luminal cancers are important to understand and assess chemopreventive and chemotherapeutic interventions. However, the ability to assess tumor growth and response without animal sacrifice is limited. We assessed the ability of luminal sonography to assess the presence of tumor and its size in a surgical esophagojejunostomy model of esophageal cancer. Luminal sonography had a sensitivity of 88%, specificity of 100%, and accuracy of 93% in identifying the esophageal cancers. The tumor dimensions on luminal sonography were within 11% of autopsy measurements. Minimal tumor dimension was 2 mm and maximum 6.2 mm. The procedure was feasible without technical difficulty. In conclusion, rodent endosonography is a useful technique that can accurately determine the presence of tumors as well as their dimensions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
SEER, Incidence and US mortality trends by primary cancer site. Cancer statistics review. National Cancer Institute, 1999.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106–30.
El-Rifai W, Frierson HF Jr, Moskaluk CA, Harper JC, Petroni GR, Bissonette EA, et al. Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Gastroenterology 2001;121(3):592–8.
Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999;20(9):1801–8.
Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 1999;20(1):51–8.
Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000;60(7):1864–70.
Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60(18):5040–4.
Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62(1):28–32.
Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 2002;122(4):1101–12.
Taketo MM. Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 2006;25(57):7522–30.
Craft N, Bruhn KW, Nguyen BD, Prins R, Liau LM, Collisson EA, et al. Bioluminescent imaging of melanoma in live mice. J Invest Dermatol 2005;125(1):159–65.
Ottewell PD, Coleman RE, Holen I. From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 2006;96(2):101–13.
Winnard PT Jr, Kluth JB, Raman V. Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia (New York) 2006;8(10):796–806.
Ho YS, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. Reduced fertility in female mice lacking copper-zinc superoxide dismutase. J Biol Chem 1998;273(13):7765–9.
Dann CT, Alvarado AL, Hammer RE, Garbers DL. Heritable and stable gene knockdown in rats. Proc Natl Acad Sci U S A 2006;103(30):11246–51.
Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3(9):676–84.
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83(10):2049–53.
Streitz JM Jr, Ellis FH Jr, Gibb SP, Balogh K, Watkins E Jr. Adenocarcinoma in Barrett’s esophagus. A clinicopathologic study of 65 cases. Ann Surg 1991;213(2):122–5.
Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett’s oesophagus. Gut 1992;33(11):1454–8.
Thomas P, Doddoli C, Lienne P, Morati N, Thirion X, Garbe L, et al. Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br J Surg 1997;84(1):119–25.
Moreto M. Diagnosis of esophagogastric tumors. Endoscopy 2003;35(1):36–42.
Hunerbein M, Ghadimi BM, Haensch W, Schlag PM. Transendoscopic ultrasound of esophageal and gastric cancer using miniaturized ultrasound catheter probes. Gastrointest Endosc 1998;48(4):371–5.
Menzel J, Hoepffner N, Nottberg H, Schulz C, Senninger N, Domschke W. Preoperative staging of esophageal carcinoma: miniprobe sonography versus conventional endoscopic ultrasound in a prospective histopathologically verified study [see comments]. Endoscopy 1999;31(4):291–7.
Acknowledgment
The authors would like to acknowledge the support of the Fitermann Foundation, Mayo Foundation, and NIH grant CA110022-01.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buttar, N.S., Wiersema, M.J., Wang, K.K. et al. Rodent Endosonography to Monitor Esophageal Cancer. Int J Gastrointest Canc 37, 84–90 (2006). https://doi.org/10.1007/s12029-007-0006-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-007-0006-4